Free Trial
OTCMKTS:TRUMY

Terumo (TRUMY) Stock Price, News & Analysis

Terumo logo
$18.33 -0.47 (-2.50%)
As of 11:47 AM Eastern

About Terumo Stock (OTCMKTS:TRUMY)

Key Stats

Today's Range
$18.27
$18.50
50-Day Range
$17.70
$19.72
52-Week Range
$14.06
$21.22
Volume
24,719 shs
Average Volume
160,752 shs
Market Capitalization
$27.14 billion
P/E Ratio
35.25
Dividend Yield
0.98%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Terumo Corporation is a global medical technology company specializing in the development, manufacturing and distribution of a broad range of medical devices and supplies. The company operates through key segments that include Cardiac & Vascular, General Hospital, Blood Management and Diabetes Care. Its product portfolio encompasses vascular intervention solutions, heart-lung bypass systems, infusion pumps, catheter devices and blood collection and processing equipment, catering to hospitals, clinics and laboratory settings worldwide.

Founded in 1921 as a producer of precision thermometers by Dr. Kitasato Shibasaburo, Terumo has grown from its early roots in temperature measurement into a diversified medtech leader. Over the decades, the company has expanded its expertise through strategic R&D investments, acquisitions and partnerships, broadening its capabilities in minimally invasive therapies, automated blood processing and wearable glucose monitoring systems.

Terumo’s innovation footprint is supported by research and development centers and manufacturing facilities across Asia, North America and Europe. This global network enables the company to adapt its offerings to regional healthcare needs, collaborate with leading medical institutions and accelerate the commercialization of new technologies. Key products, such as coated stents, vascular closure devices and advanced infusion sets, serve a wide spectrum of therapeutic areas including cardiology, oncology and critical care.

Headquartered in Tokyo, Japan, Terumo is overseen by a management team led by the President and Chief Executive Officer, supported by a board of directors and executive officers. Under this leadership, the company continues to pursue growth through innovation, operational excellence and expansion into emerging healthcare markets, reinforcing its mission to contribute to society by saving and improving lives.

AI Generated. May Contain Errors.

Receive TRUMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Terumo and its competitors with MarketBeat's FREE daily newsletter.

TRUMY Stock News Headlines

Terumo Corp ADR TRUMY
I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
See More Headlines

TRUMY Stock Analysis - Frequently Asked Questions

Terumo's stock was trading at $19.50 at the beginning of the year. Since then, TRUMY stock has decreased by 6.0% and is now trading at $18.33.
View the best growth stocks for 2025 here
.

Terumo Corp. (OTCMKTS:TRUMY) announced its earnings results on Wednesday, May, 14th. The company reported $0.08 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by $0.07. The company earned $1.79 billion during the quarter, compared to analysts' expectations of $1.79 billion. Terumo had a trailing twelve-month return on equity of 8.48% and a net margin of 11.28%.

Terumo shares split before market open on Thursday, March 28th 2024.The 2-1 split was announced on Thursday, March 28th 2024. The newly created shares were payable to shareholders after the closing bell on Thursday, March 28th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Shares of TRUMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/14/2025
Today
6/30/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Personal Services
Current Symbol
OTCMKTS:TRUMY
Previous Symbol
NASDAQ:TRUMY
Employees
30,000
Year Founded
1964

Profitability

Trailing P/E Ratio
36.15
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$772.05 million
Pretax Margin
14.92%

Debt

Sales & Book Value

Annual Sales
$6.80 billion
Cash Flow
$0.90 per share
Price / Cash Flow
20.90
Book Value
$6.10 per share
Price / Book
3.08

Miscellaneous

Outstanding Shares
1,480,560,000
Free Float
N/A
Market Cap
$27.83 billion
Optionable
Not Optionable
Beta
0.81

Social Links

12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (OTCMKTS:TRUMY) was last updated on 6/30/2025 by MarketBeat.com Staff
From Our Partners